A. Rezvani

发表

Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation.

D. Tierney, S. Singhal, Ted Kim, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab resistance.

D. Maloney, A. Rezvani, David G Maloney, 2011, Best practice & research. Clinical haematology.

Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

D. Blough, G. McDonald, J. McCune, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prevention of graft-vs.-host disease

R. Storb, A. Rezvani, Andrew R. Rezvani, 2012, Expert opinion on pharmacotherapy.

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.

K. Davis, Y. Natkunam, M. Ozawa, 2020, Blood.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

K. Davis, Y. Natkunam, M. Ozawa, 2021, Nature Medicine.

Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia.

K. Ballen, L. Metheny, A. Rezvani, 2021, Transplantation and cellular therapy.

Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

P. Lavori, D. Miklos, R. Hoppe, 2019, Blood advances.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using total lymphoid irradiation and anti-thymocyte globulin conditioning

B. Efron, H. Kohrt, D. Miklos, 2015, Bone Marrow Transplantation.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.

D. Miklos, R. Negrin, L. Muffly, 2017, Blood advances.

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

Sonali M. Smith, S. Devine, S. Jaglowski, 2017, Journal of Hematology & Oncology.

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.

D. Miklos, R. Negrin, L. Muffly, 2018, Blood advances.

Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma

D. Iberri, D. Miklos, M. Liedtke, 2020, Bone Marrow Transplantation.

Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.

D. Miklos, R. Negrin, L. Muffly, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, A. Zelenetz, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.

R. Storb, A. Rezvani, Andrew R. Rezvani, 2008, Journal of autoimmunity.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

J. Byrd, M. Dyer, A. Logan, 2016, Blood.

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.

D. Miklos, R. Hoppe, R. Negrin, 2020, Blood advances.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.

D. Miklos, K. Cunanan, L. Muffly, 2022, Transplantation and cellular therapy.

Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes

B. Sandmaier, A. Rezvani, Andrew R. Rezvani, 2013, Current opinion in hematology.

A Canine Model of Chronic Graft-versus-Host Disease.

R. Storb, L. Kean, G. Sale, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

B. Storer, G. McDonald, J. McCune, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lymphoma and transplantation

A. Rezvani, Andrew R. Rezvani, 2015 .

Lymphoma and transplantation : historical perspective

A. Rezvani, Andrew R. Rezvani, 2015 .

Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.

B. Storer, F. Appelbaum, E. Warren, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation: the state of the art

R. Storb, A. Rezvani, Andrew R. Rezvani, 2010, Expert review of hematology.

Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies

R. Storb, A. Rezvani, Andrew R. Rezvani, 2008, Expert opinion on biological therapy.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.

D. Miklos, B. Sahaf, Sai-Wen Tang, 2019, JCI insight.

Introduction to Hematopoietic Cell Transplantation

H. Deeg, A. Rezvani, Andrew R. Rezvani, 2016 .

Inducible Costimulator (ICOS) Up-Regulation on Activated T Cells in Chronic Graft-Versus-Host Disease After Dog Leukocyte Antigen–Nonidentical Hematopoietic Cell Transplantation: A Potential Therapeutic Target

R. Storb, M. Mielcarek, Masahiko Sato, 2013, Transplantation.

Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.

O. Frankfurt, G. Schiller, P. Stiff, 2021, Blood.